TBPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Theravance Biopharma Inc (TBPH) is not a good buy for a beginner investor with a long-term focus at this time. The company's recent Phase 3 trial failure, analyst downgrades, and lack of clear growth catalysts outweigh its restructuring efforts and cash reserves. Additionally, technical indicators and options data do not suggest a strong entry point.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is at 35.484, in the neutral zone, providing no clear signal. Moving averages are converging, showing indecision in the price trend. Support is at 13.435, and resistance is at 14.119, with the current price near resistance levels.
The company has $326.5 million in cash reserves, achieved record non-GAAP profitability in Q4 2025, and is implementing a restructuring plan targeting significant cost reductions.
The Phase 3 CYPRESS trial failure has led to the termination of the ampreloxetine program and a 26% drop in share price. Analysts have downgraded the stock, citing limited visibility into future growth drivers. The company is undergoing a strategic review, which adds uncertainty.
In Q4 2025, revenue increased by 11.39% YoY to $45.9 million. However, net income dropped by -493.02% YoY to $61.0 million, and EPS declined by -470.97% YoY to 1.15. Gross margin fell to 0, reflecting significant challenges in profitability.
Recent analyst actions include multiple downgrades and price target reductions due to the CYPRESS trial failure. Analysts see limited upside potential and have removed ampreloxetine expectations from their models.
